Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

NCT05740215 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: F520
DRUG: Lenvatinib

Sponsor

Shandong New Time Pharmaceutical Co., LTD